Global Hematology Partnering Deal Trends, Players and Financials Analysis 2010-2016

Feb 04, 2016, 10:10 ET from Research and Markets

DUBLIN, Feb. 4, 2016 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Global Hematology Partnering 2010-2016: Deal trends, players and financials" company profile to their offering.

Global Hematology Partnering 2010 to 2016 provides the full collection of Hematology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Hematology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Hematology deals.

The report presents financial deal terms values for Hematology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Hematology dealmaking trends.

Global Hematology Partnering 2010 to 2016 includes:

  • Trends in Hematology dealmaking in the biopharma industry since 2010
  • Analysis of Hematology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Hematology deal contract documents
  • Comprehensive access to over 3500 Hematology deal records
  • The leading Hematology deals by value since 2010
  • Most active Hematology dealmakers since 2010

In Global Hematology Partnering 2010 to 2016, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Hematology dealmaking

Chapter 3 - Financial deal terms for Hematology partnering

Chapter 4 - Leading Hematology deals and dealmakers

Chapter 5 - Hematology contract document directory

Chapter 6 - Hematology dealmaking by therapeutic target

For more information visit

Media Contact:

Laura Wood , +353-1-481-1716,



SOURCE Research and Markets